AC IMMUNE SA (ACIU)       2.3  +0.23 (+11.11%)

2.3  +0.23 (+11.11%)

CH0329023102 - Common Stock - After market: 2.33 +0.03 (+1.3%)

AC IMMUNE SA2.3

NASDAQ:ACIU (12/8/2022, 6:10:35 PM)+0.23 (+11.11%)

After market: 2.33 +0.03 (+1.3%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 10-28 2022-10-28/bmo Earnings (Next) 03-20 2023-03-20
Ins Owners N/A Inst Owners 112.23%
Market Cap 192.17M Shares 83.55M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.67
IPO 09-23 2016-09-23

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACIU Daily chart

Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Company Info

AC IMMUNE SA

EPFL Innovation Park, Building B

Lausanne VAUD 1015

P: 41213459121.0

CEO: Andrea Pfeifer

Employees: 143

Website: https://www.acimmune.com/

ACIU News

News Image9 days ago - AC Immune SAAC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further DevelopmentNews Image9 days ago - AC Immune SAAC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical...

News Image16 days ago - AC Immune SAAC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD ConferenceNews Image16 days ago - AC Immune SAAC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on...

News Image17 days ago - MarketBeatIs Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

News Imagea month ago - AC Immune SAAC Immune to Present at the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...

ACIU Twits

Here you can normally see the latest stock twits on ACIU, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example